# V1 Empirics Check — openai/gpt-5.1-codex-mini (Variant A)

**Model:** openai/gpt-5.1-codex-mini
**Variant:** A
**Date:** 2026-03-25T13:18:13.291884

---

**Idea Fidelity**

The paper largely follows the manifest: it evaluates the October 2021 Greater London ULEZ expansion using station-level NO₂ data and a difference-in-differences/event-study framework. However, the implementation diverges in several notable ways from the stated plans. The manifest envisaged 212+ stations (52 treated, 160 controls) from the LAQN, while the paper ultimately analyzes 77 stations (41 treated, 36 controls). This reduction is not explained---is it due to data availability, attrition, or quality filters? The manifest also promised a Callaway–Sant’Anna estimator with outer-London stations treated in August 2023 and “dose-response: distance from ULEZ boundary,” but the paper mostly sticks to the canonical two-way fixed-effects DiD, with only a brief reference to Callaway–Sant’Anna and simple distance splits (near vs. far). The stated placebo and weekend/weekday analyses are not fully presented (e.g., no weekend/weekday results). The paper, moreover, does not extend to the auxiliary health outcomes (COPD/asthma admissions) mentioned in the manifest. These omissions weaken the fidelity to the original design.

**Summary**

The paper studies the October 2021 expansion of London’s Ultra Low Emission Zone using a station-month panel of NO₂ concentrations and a difference-in-differences specification comparing inner-London (treated) to outer-London (control) stations. The estimated effect is a modest −1.6 μg/m³ reduction in monthly NO₂ (3.3 percent), which is not statistically significant and appears sensitive to COVID-period exclusion and the inclusion of borough trends. The author concludes that any marginal effect of the expansion was limited and potentially obscured by pandemic-induced traffic shifts and secular fleet modernization.

**Essential Points**

1. **Sample Selection and Representativeness.** The paper does not explain why only 77 stations appear in the final panel, whereas the manifest promised over 212 stations. Given that representativeness of treated and control stations is central for DiD credibility, the authors need to clarify the data cleaning steps and show that the retained stations still cover the intended geographic scope (e.g., boundary vs. interior, boroughs). If the reduction is due to missing post-2021 data or quality filters, then attrition could be endogenous to treatment (inner stations being older/more rural). Reporting a table that compares included vs. excluded stations on pre-treatment NO₂, proximity to boundary, and type (roadside vs. background) would assuage concerns.

2. **Parallel Trends and Treatment Timing.** The parallel-trends assumption is strained by two factors: (i) the pre-treatment trends show seasonal variation (e.g., the elevated $t=-12$ coefficient), and (ii) the placebo at October 2019 yields a significant negative coefficient, indicating inner stations were on a different trajectory during COVID even before the 2021 expansion. The paper addresses this by excluding March 2020–June 2021, but this exclusion removes 15 months of data, weakening statistical power and possibly introducing selection if the pandemic response had lingering differential effects. A more thorough treatment of the pandemic confound in the identifying assumption is needed—e.g., include station-specific COVID mobility controls or flexible time trends around 2020 and 2021 that allow inner and outer stations to diverge. Without that, it is unclear whether the null result arises from a true zero effect or from uncontrolled pre-trends.

3. **Control Group Validity (Spillovers and Contamination).** Outer London stations are used as controls up to August 2023 when they join the ULEZ, but some are within a few kilometers of the inner zone and thus could experience spillovers or anticipatory effects before August 2023. The heterogeneity analysis that compares “near” vs. “far” stations suggests a counterintuitive pattern (larger point estimates further inside), which could reflect such spillovers or differential trends. The paper should provide evidence that control stations remained unaffected until August 2023—e.g., by showing no effect at stations just outside the boundary prior to 2021 or by instrumenting treatment with distance to the boundary. Without this, the DiD estimates may conflate treatment with boundary spillovers, biasing toward the null.

If more than these issues would need to be raised, the paper should be rejected outright; however, the concerns above are manageable with additional analysis.

**Suggestions**

The paper is asking an important question, and the station-level data offer rich variation. The following recommendations aim to strengthen causal inference and interpretability:

1. **Revisit the sample construction and document attrition.** Provide a flowchart (or detailed description) of how the sample went from >200 stations to 77, including the reasons for excluding stations (missing months, failed quality checks, etc.). Report summary statistics for excluded vs. included stations so readers can assess whether the final panel is still representative of boundary vs. inner vs. outer locations. If specific types of stations (e.g., those near the circular) were systematically dropped, consider re-running the analysis with a broader inclusion threshold (e.g., allowing 60% month coverage) or using imputation methods for missing months to recover more sites.

2. **Strengthen the parallel-trends assessment.** The event study should report confidence bands for the leads/lags and account for the seasonality and pandemic shocks more explicitly. Consider augmenting the specification with the following:
   - Include station-specific linear or quadratic trends interacted with indicators for the pre-COVID, COVID, and post-COVID periods to allow differential trajectories.
   - Introduce time-varying covariates capturing mobility or traffic intensity (Google Mobility, TfL counts) and interacting them with treatment status to absorb differential pandemic responses.
   - Estimate the DiD separately for sub-periods (pre-2019 vs. 2019–2021) to check for consistent pre-trends.
   - Present the Rambachan–Roth robustness results visually to show how much parallel-trend violation the estimate can tolerate before the sign flips.

3. **Address potential spillovers and contamination of the control group.** The control stations might already feel the effects of the ULEZ via diverted traffic or anticipatory behavior. Some ideas:
   - Construct a spatial buffer around the inner zone (e.g., within 2 km) and either exclude these stations from the control group or treat them separately to test for spillovers.
   - Use a regression discontinuity design at the boundary (e.g., comparing stations on either side within a narrow band), which would provide an alternative estimate less sensitive to outer-London trends.
   - Include distance-to-boundary interacted with post-treatment indicators to model how effects decay with distance. The current near/far split is a good start, but a continuous dose-response (e.g., spline) might reveal more structure.
   - If available, use data on enforcement camera density or compliance rates to argue that outer stations remained untreated until August 2023.

4. **Present the Callaway–Sant’Anna estimates in more detail.** The paper mentions the group-time ATT but reports only the aggregate near-zero estimate. A table or figure showing the estimated ATT for each post-treatment month (or bin) would help readers understand whether there are dynamic effects. Moreover, the method naturally accommodates the staggered treatment (outer stations treated in 2023), so clarifying how the August 2023 expansion is handled (e.g., by censoring post-2023 data or treating outer stations as not-yet-treated) would improve transparency.

5. **Explore additional outcomes or mechanisms to triangulate findings.** The manifest mentioned PM2.5 and emergency admissions; if the data exist, even limited analysis could bolster the conclusions. For instance, if PM2.5 shows similar null patterns, it strengthens the claim that the marginal effect was small. If health data are not feasible, consider using traffic counts or vehicle fleet composition data (e.g., share of compliant vehicles in inner vs. outer boroughs) to demonstrate that much of the compliance effect occurred before 2021. Even correlational evidence on fleet composition would support the “front-loaded compliance” narrative.

6. **Contextualize the “null” result within statistical power.** The paper already notes that the MDE at 80% power is ~2.9 μg/m³, but readers may benefit from expressing the effect as a share of the typical inner-minus-outer gap or as the implied avoided exceedances of WHO guidelines. This would help interpret whether the null result is policy-relevant or simply a consequence of limited precision. Similarly, consider calibrating the implied health benefits (even with large error bands) to show the magnitude of the policy trade-offs.

7. **Clarify the role of the 2023 expansion in the analysis.** Since the control group eventually becomes treated, make clear whether the sample stops before August 2023 (as stated in the introduction) or if data beyond that date are included (perhaps to check for second-wave effects). If the sample ends in August 2023, explain why the later expansion is only discussed qualitatively (e.g., the paper could mention that it prevented a longer post-period).

8. **Enhance robustness by using alternative clustering/standard error methods.** With 77 stations, station-level clustering is standard, but reporting placebo inference using wild-bootstrap or the “clustered-by-treatment” approach would reassure readers. Also, consider bootstrapping the Callaway–Sant’Anna estimates to show distributional stability.

In sum, the paper addresses a salient policy question but would benefit from more thorough documentation of the sample, a deeper treatment of the pandemic confound, and more systematic handling of spatial spillovers. Addressing these points would strengthen confidence that the null finding reflects policy reality rather than identification weaknesses.
